Gyre director cancels 250,000 share option grant

GYRE Therapeutics director Zhang Ping reported a cancellation of stock options previously granted by the company.

Rhea-AI Filing Summary

GYRE Therapeutics director Zhang Ping reported a cancellation of stock options previously granted by the company. A stock option covering 250,000 shares of common stock with a $10.18 exercise price and a May 27, 2035 expiration was disposed of back to the issuer.

According to the disclosure, the option was canceled by mutual agreement, and the company will provide consideration whose form and amount it will determine, but this consideration will not have economic value. The canceled grant would have begun vesting on May 27, 2026, with monthly vesting over three additional years, and no shares remain from this option after the transaction.

Insider Trade Summary

Disposition: 250,000 shares

Disposition 1 txn

Insider Zhang Ping

Role Director

Type	Security	Shares	Price	Value
Disposition	Stock Option (Right to Buy)	250,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct)

Footnotes (2)

1. F1. The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value.
2. F2. The canceled option represented a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which would have vested on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Options canceled: 250,000 shares Exercise price: $10.18 per share Expiration date: May 27, 2035 +3 more

6 metrics

Options canceled 250,000 shares Stock option right to buy common stock disposed to issuer

Exercise price $10.18 per share Conversion or exercise price of canceled option

Expiration date May 27, 2035 Original expiration date of canceled stock option

Post-transaction option balance 0 shares Total shares following transaction for this option grant

Initial vesting date May 27, 2026 25% of canceled option would have vested on this date

Remaining vesting period 3 years monthly Remaining 75% would vest in equal monthly installments

Key Terms

Disposition to issuer, Stock Option (Right to Buy), vested, economic in value, +1 more

5 terms

Disposition to issuer financial

"transaction_action: issuer disposition"

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

vested financial

"25% of which would have vested on May 27, 2026"

economic in value financial

"provided that such consideration shall not be economic in value"

common stock financial

"a total of 250,000 shares of the Issuer's common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GYRE director Zhang Ping report on this Form 4?

Zhang Ping reported a disposal of a stock option back to Gyre Therapeutics. The option covered 250,000 shares of common stock and was canceled by mutual agreement between the director and the company.

How many GYRE stock options were canceled in Zhang Ping’s Form 4 filing?

The filing shows cancellation of a stock option for 250,000 shares of Gyre Therapeutics common stock. This option represented a right to buy those shares, subject to vesting conditions and a specified exercise price and expiration date.

What was the exercise price and expiration date of Zhang Ping’s canceled GYRE option?

The canceled stock option had a conversion or exercise price of $10.18 per share and an expiration date of May 27, 2035. These terms defined the cost and timeframe to purchase Gyre Therapeutics common shares under the grant.

Will Zhang Ping receive compensation for canceling the GYRE stock option?

The company will provide consideration for the cancellation, but it will not be economic in value. The form and amount of this consideration will be determined solely by Gyre Therapeutics, according to the disclosure language provided.

What was the vesting schedule for the canceled GYRE stock option grant?

The canceled option would have vested 25% on May 27, 2026, with the remaining 75% vesting in equal monthly installments over the following three years. Vesting was contingent on Zhang Ping’s continued service to Gyre Therapeutics through each vesting date.

Does Zhang Ping retain any of this specific GYRE option position after the transaction?

No, the Form 4 shows total shares following the transaction as zero for this option. This indicates the entire 250,000-share stock option grant described was canceled and no portion of this particular grant remains outstanding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 09:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zhang Ping

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.18	05/14/2026		D(1)			250,000	(2)	05/27/2035	Common Stock	250,000	$0(1)	0	D

Explanation of Responses:

1. The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value.

2. The canceled option represented a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which would have vested on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Thomas Eastling as Attorney-in-Fact for Ping Zhang	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)